Imageguided radiotherapy of the prostate using daily CBCT: The feasibility and likely benefit of implementing a margin reduction

British Journal of Radiology

Volumn 87, Issue 1044, 2014, Pages

  Maund, I F ^a   Benson, R J ^a,b   Fairfoul, J ^b   Cook, J ^b   Huddart, R ^c   Poynter, A ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b PETERBOROUGH CITY HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED STUDY; DOSE VOLUME HISTOGRAM; FEASIBILITY STUDY; HISTOGRAM; HUMAN; IMAGE GUIDED RADIOTHERAPY; MALE; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIATION DOSE REDUCTION; TREATMENT OUTCOME; COMPUTER ASSISTED RADIOTHERAPY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL;

CONE-BEAM COMPUTED TOMOGRAPHY; FEASIBILITY STUDIES; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; TREATMENT OUTCOME;

EID: 84911893986     PISSN: 00071285     EISSN: 1748880X     Source Type: Journal    
DOI: 10.1259/bjr.20140459     Document Type: Article

References (47)

1. Office for National Statistics Mortality Statistics. Deaths registrered in 2010, England and Wales. London, UK: National Statistics; 2011.
2. Gulliford SL, Foo K, Morgan RC, Aird EG, Bidmead AM, Critchley H, et al. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys 2010; 76: 747-54. doi: 10.1016/j.ijrobp.2009.02.025
3. Geinitz H, Zimmermann FB, Thamm R, Erber C, Müller T, Keller M, et al. Late rectal symptoms and quality of life after conformal radiation therapy for prostate cancer. Radio-ther Oncol 2006; 79: 341-7.
4. Aubry JF, Beaulieu L, Girouard LM, Aubin S, Tremblay D, Laverdière J, et al. Measurements of intrafraction motion and interfrac-tion and intrafraction rotation of prostate by three-dimensional analysis of daily portal imaging with radiopaque markers. Int J Radiat Oncol Biol Phys 2004; 60: 30-9.
5. Chen J, Lee RJ, Handrahan D, Sause WT. Intensity-modulated radiotherapy using implanted fiducial markers with daily portal imaging: assessment of prostate organ motion. Int J Radiat Oncol Biol Phys 2007; 68: 912-19.
6. Bylund KC, Bayouth JE, Smith MC, Hass AC, Bhatia SK, Buatti JM. Analysis of interfrac-tion prostate motion using megavoltage cone beam computed tomography. Int J Radiat Oncol Biol Phys 2008; 72: 949-56. doi: 10.1016/j.ijrobp.2008.07.002
7. Chandra A, Dong L, Huang E, Kuban DA, O'Neill L, Rosen I, et al. Experience of ultrasound-based daily prostate localization. Int J Radiat Oncol Biol Phys 2003; 56: 436-47.
8. Ten Haken RK, Foreman JD, Heimburger DK, Gerhardsson A, McShan DL, Perez-Tamayo C, et al. Treatment planning issues related to prostate movement in response to differential filling of the rectum and bladder. Int J Radiat Oncol Biol Phys 1991; 20: 1317-24.
9. Schallenkamp JM, Herman MG, Kruse JJ, Pisansky TM. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys 2005; 63: 800-11.
10. Mohan DS, Kupelian PA, Willoughby TR. Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland. Int J Radiat Oncol Biol Phys 2000; 46: 575-80.
11. Burnet NG, Adams EJ, Fairfoul J, Tudor GS, Hoole AC, Routsis DS, et al. Practical aspects of implementation of helical tomotherapy for intensity-modulated and image-guided radiotherapy. Clin Oncol (R Coll Radiol) 2010; 22: 294-312. doi: 10.1016/j.clon.2010.02.003
12. Barney BM, Lee RJ, Handrahan D, Welsh KT, Cook JT, Sause WT. Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography (CBCT). Int J Radiat Oncol Biol Phys 2011; 80: 301-5. doi: 10.1016/j.ijrobp.2010.06.007
13. Boda-Heggemann J, Lohr F, Wenz F, Flentje M, Guckenberger M. kV cone-beam CT-based IGRT: a clinical review. Strahlenther Onkol 2011; 187: 284-91. doi: 10.1007/s00066-011-2236-4
14. Moseley DJ, White EA, Wiltshire KL, Rosewall T, Sharpe MB, Siewerdsen JH, et al. Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 2007; 67: 942-53.
15. Tudor GS, Rimmer YL, Nguyen TB, Cowen MA, Thomas SJ. Consideration of the likely benefit from implementation of prostate image-guided radiotherapy using current margin sizes: a radiobiological analysis. Br J Radiol 2012; 85: 1263-71. doi: 10.1259/bjr/27924223
16. Khoo VS, Dearnaley DP. Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer-the CHHiP trial. Clin Oncol (R Coll Radiol) 2008; 20: 12-14.
17. Sanchez-Nieto B, Nahum AE. BIOPLAN: software for the biological evaluation of radiotherapy treatment plans. Med Dosim 2000; 25: 71-6.
18. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988; 15: 1299-305.
19. Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res 1985; 104: S13-19.
20. Kutcher GJ, Burman C. Calculation of complication probability factors for non uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys 1988; 16: 1623-30.
21. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010; 76(Suppl. 3): S123-9. doi: 10.1016/j.ijrobp.2009.03.078
22. Pawlowski JM, Yang ES, Malcolm AW, Coffey CW, Ding GX. Reduction of dose delivered to organs at risk in prostate cancer patients via image-guided radiation therapy. Int J Radiat Oncol Biol Phys 2010; 76: 924-34. doi: 10.1016/j.ijrobp.2009.06.068
23. Hatton JA, Greer PB, Tang C, Wright P, Capp A, Gupta S, et al. Does the planning dose-volume histogram represent treatment doses in image-guided prostate radiation therapy? Assessment with cone-beam computerised tomography scans. Radiother Oncol 2011; 98: 162-8. doi: 10.1016/j.radonc.2011.01.006
24. Kupelian PA, Langen KM, Zeidan OA, Meeks SL, Willoughby TR, Wagner TH, et al. Daily variations in delivered doses in patients treated with radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2006; 66: 876-82.
25. Sripadam R, Stratford J, Henry AM, Jackson A, Moore CJ, Price P. Rectal motion can reduce CTV coverage and increase rectal dose during prostate radiotherapy: a daily cone-beam CT study. Radiother Oncol 2009; 90: 312-17. doi: 10.1016/j.radonc.2008.07.031
26. Lebesque JV, Bruce AM, Kroes AP, Touw A, Shouman RT, van Herk M. Variation in volumes, dose-volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33: 1109-19.
27. Engels B, Tournel K, Soete G, Storme G. Assessment of rectal distension in radiotherapy of prostate cancer using daily megavolt-age CT image guidance. Radiother Oncol 2009; 90: 377-81. doi: 10.1016/j. radonc.2008.12.005
28. Anderson NS, Yu JB, Peschel RE, Decker RH. A significant decrease in rectal volume and diameter during prostate IMRT. Radiother Oncol 2011; 98: 197-91. doi: 10.1016/j. radonc.2010.12.005
29. Stasi M, Munoz F, Fiorino C, Pasquino M, Baiotto B, Marini P, et al. Emptying the rectum before treatment delivery limits the variations of rectal dose-volume parameters during 3DCRT of prostate cancer. Radiother Oncol 2006; 80: 363-70.
30. Hammoud R, Patel SH, Pradhan D, Kim J, Guan H, Li S, et al. Examining margin reduction and its impact on dose distribution for prostate cancer patients undergoing daily cone-beam computed tomography. Int J Radiat Oncol Biol Phys 2008; 71: 265-73. doi: 10.1016/j.ijrobp.2008.01.015
31. Crehange G, Mirjolet C, Gauthier M, Martin E, Truc G, Peignaux-Casasnovas K, et al. Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer. Radiother Oncol 2012; 103: 244-6. doi: 10.1016/j. radonc.2011.10.025
32. White EA, Brock KK, Jaffray DA, Catton CN. Inter-observer variability of prostate delineation on cone beam computerised tomography images. Clin Oncol (R Coll Radiol) 2009; 21: 32-8. doi: 10.1016/j. clon.2008.11.007
33. Lütgendorf-Caucig C, Fotina I, Stock M, Pötter R, Goldner G, Georg D. Feasibility of CBCT-based target and normal structure delineation in prostate cancer radiotherapy: multi-observer and image multi-modality study. Radiother Oncol 2011; 98: 154-61. doi: 10.1016/j.radonc.2010.11.016
34. Kotte AN, Hofman P, Lagendijk JJ, van Vulpen M, van der Heide UA. Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys 2007; 69: 419-25.
35. Nederveen AJ, van der Heide UA, Dehnad H, van Moorselaar RJ, Hofman P, Lagendijk JJ. Measurements and clinical consequences of prostate motion during a radiotherapy fraction. Int J Radiat Oncol Biol Phys 2002; 53: 206-14.
36. Ghilezan MJ, Jaffray DA, Siewerdsen JH, Van Herk M, Shetty A, Sharpe MB, et al. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys 2005; 62: 406-17.
37. Curtis W, Khan M, Magnelli A, Stephans K, Tendulkar R, Xia P. Relationship of imaging frequency and planning margin to account for intrafraction prostate motion: analysis based on real-time monitoring data. Int J Radiat Oncol Biol Phys 2013; 85: 700-6. doi: 10.1016/j.ijrobp.2012.05.044
38. Spezi E, Downes P, Jarvis R, Radu E, Staffurth J. Patient-specific three-dimensional concomitant dose from cone beam computed tomography exposure in image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2012; 83: 419-26. doi: 10.1016/j. ijrobp.2011.06.1972
39. Kim DW, Chung WK, Yoon M. Imaging doses and secondary cancer risk from kilo-voltage cone-beam CT in radiation therapy. Health Phys 2013; 104: 499-503. doi: 10.1097/HP.0b013e318285c685
40. Fiorino C, Reni M, Bolognesi A, Cattaneo GM, Calandrino R. Intra-and inter-observer variability in contouring prostate and seminal vesicles: implications for conformal treatment planning. Radiother Oncol 1998; 47: 285-92.
41. Roeske JC, Forman JD, Mesina CF, He T, Pelizzari CA, Fontenla E, et al. Evaluation of changes in the size and location of the prostate, seminal vesicles, bladder, and rectum during a course of external beam radiation therapy. Int J Radiat Oncol Biol Phys 1995; 33: 1321-9.
42. Liang J, Wu Q, Yan D. The role of seminal vesicle motion in target margin assessment for online image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73: 935-43. doi: 10.1016/j. ijrobp.2008.10.019
43. Craig T, Battista J, van Dyk J. Limitations of a convolution method for modeling geometric uncertainties in radiation therapy. I. The effect of shift invariance. Med Phys 2003; 30: 2001-11.
44. Liu M, Moiseenko V, Agranovich A, Karvat A, Kwan W, Saleh ZH, et al. Normal tissue complication probability (NTCP) modeling of late rectal bleeding following external beam radiotherapy for prostate cancer: a test of the QUANTEC-recommended NTCP model. Acta Oncol 2010; 49: 1040-4. doi: 10.3109/0284186X.2010.509736
45. Gulliford SL, Partridge M, Sydes MR, Webb S, Evans PM, Dearnaley DP. Parameters for the Lyman Kutcher Burman (LKB) model of normal tissue complication probability (NTCP) for specific rectal complications observed in clinical practise. Radiother Oncol 2012; 102: 347-51. doi: 10.1016/j. radonc.2011.10.022
46. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002; 52: 6-13.
47. Jensen I, Carl J, Lund B, Larsen EH, Nielsen J. Radiobiological impact of reduced margins and treatment technique for prostate cancer in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP). Med Dosim 2011; 36: 130-7. doi: 10.1016/j.meddos.2010.02.004